Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 12/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316647 | 0.74 | KDM4E (0.43) | JAK2JAK1JAK3KDM4EADORA2A | |
| SCHEMBL24316522 | 0.74 | ALDH1A1 (0.48) | CYP11B2CYP11B1JAK2JAK1JAK3 | |
| SCHEMBL2031795 | 0.74 | JAK2 (0.50) | CYP11B2CYP11B1CYP19A1JAK2JAK1 | |
| SCHEMBL28417731 | 0.69 | FLT3 (0.49) | JAK2JAK1JAK3ADORA2A | |
| SCHEMBL24316792 | 0.69 | TGFBR1 (0.43) | JAK2JAK1JAK3KDM4ECYP3A4 | |
| SCHEMBL5763750 | 0.69 | TGFBR1 (0.46) | CYP11B2CYP11B1CYP19A1JAK2JAK1 | |
| SCHEMBL1353156 | 0.66 | TGFBR1 (0.50) | CYP11B2CYP11B1CYP19A1JAK2JAK1 | |
| SCHEMBL1355409 | 0.66 | ADORA2A (0.40) | CYP11B2CYP11B1CYP19A1JAK2JAK1 | |
| SCHEMBL14041215 | 0.66 | TGFBR1 (0.43) | CYP11B2CYP11B1CYP19A1CYP3A4ADORA2A | |
| SCHEMBL3787763 | 0.66 | ADORA2A (0.40) | CYP11B2CYP11B1JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-03-21 | — | — | US | disclosed |
| EP-4214198-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2023-07-26 | — | — | EP | disclosed |
| CN-116323582-A | Heteroaromatic ring compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | CYP2D6, CYP3A7, CYP2F1 | CYP11B2 9/4885CYP11B1 16/4885CYP19A1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.